Effects of low-dose esketamine on postoperative depressive status and immune function in patients with acoustic neuroma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084537

Enrollment

Unknown

Registered

2024-05-20

Start date

2024-06-04

Completion date

Unknown

Last updated

2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acoustic neuroma

Interventions

C group:General anesthesia + intraoperative pump saline + postoperative sufentanil/palonosetron analgesia

S group:General anesthesia + intraoperative pump esketamine + postoperative esketamine/sufentanil/palonosetron analgesia

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients with acoustic neuroma disease requiring surgical treatment under general anesthesia; 2.Aged 18-75 years, gender unlimited; 3.ASA grades II-III; 4.Participate in the study voluntarily and sign the informed consent;

Exclusion criteria

Exclusion criteria: 1.Patients with moderate to severe anxiety disorder or depression before surgery, or who are receiving medication, and patients with a history of serious mental disorders (except depression and anxiety disorder); 2.Patients with history of esketamine allergy; 3.Increased intraocular or intracranial pressure; 4.Patients with poorly controlled or untreated hypertension; 5.Patients with ischemic heart disease and congestive heart failure; 6.Hyperthyroidism/hyperadrenal function: such as primary aldehyde, pheochromocytoma, etc. 7.Patients with history of chronic pain or opioid use or drug use; 8.Patients with a family history of malignant hyperthermia or a high risk of malignant hyperthermia (such as strabismus, scoliosis, etc.); 9.Any other conditions that caused the patient to be unable to cooperate with the study, such as language comprehension difficulties, postoperative complications, etc.

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative depressive state;	—

Secondary

Measure	Time frame
Sleep quality;Visual analogue scale;Cumulative intraoperative opioid consumption;Use of remedial analgesics within 48h after surgery;Serum immunoglobulin Ig A, Ig G, Ig M levels in peripheral blood;CD3+,CD4+, CD8+, CD4+/CD8+ levels of peripheral blood lymphocyte subsets;	—

Countries

China

Contacts

Public ContactWang Yaozhu

Shandong Second Provincial General Hospital, Shandong Provincial ENT Hospital

wyz1990411788@163.com+86 531 83086293

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 4, 2026